NOVONIX Limited filings document foreign-issuer reporting for an ADR-listed battery materials and technology company. Its Form 6-K reports furnish ASX announcements, operating and financial results, material-event disclosures, material agreements, shareholder voting matters, and governance updates.
Company filings also record capital-structure activity such as applications for quotation of ordinary fully paid shares, notifications of unquoted equity securities, employee incentive performance rights, and director interest notices. These disclosures connect NOVONIX's public reporting with its ordinary shares, American depositary shares, incentive securities, and governance obligations as an Australian issuer with U.S. reporting.
NOVONIX Ltd (NVX) reports that 68,107 new ordinary fully paid shares have been issued on September 15, 2026, for quotation on ASX as a result of performance rights converting under an employee incentive scheme. These additional shares form part of an existing quoted class and rank equally in all respects with existing ordinary shares.
Following this issue, total quoted ordinary shares are 997,852,692, while the company also has various unquoted performance rights, options, share rights, convertible notes and convertible debentures outstanding.
NOVONIX Limited (NVX) reports that a share price breach of the A$0.12 Floor Price under its funding agreement with YA II PN, Ltd has triggered an Amortisation Event. With US$35,000,000 outstanding under the convertible debenture facility, NOVONIX must pay US$7,000,000 in cash by September 21, 2026, reducing the outstanding amount to US$28,000,000. The company plans to fund this from existing cash, and additional 30‑day rolling amortisation payments may be required if the event continues.
Separately, NOVONIX reports progress with its lead customer: an initial mass production qualification C-sample of synthetic graphite anode active material met 12 of 14 specifications, with one unmet parameter within about 1% of the requirement. NOVONIX expects mass production sales to this customer to begin in the second half of 2027, subject to successful qualification.
NOVONIX Ltd (NVX) reported a larger half-year net loss as it continues to invest heavily in its Riverside synthetic graphite facility while still pre-revenue in its core battery materials business. For the six months ended June 30, 2026, the Group recorded a net loss of $24.6 million (vs $20.1 million in 2025) and negative operating cash flow of $23.1 million, leaving cash of $59.5 million and net current liabilities of about $2.5 million.
The auditor highlighted a material uncertainty about going concern, pointing to ongoing losses, cash burn, the need for additional funding, and the risk of cash redemptions under the Yorkville convertible debentures if share-price conditions trigger Amortization Events. At June 30, 2026, $35 million of Yorkville debentures remained outstanding and $33.1 million under the LGES notes, both classified as current.
Strategically, NOVONIX delivered a C-sample synthetic graphite anode to Panasonic and reaffirmed planned mass production in the second half of 2027, subject to qualification. The company raised capital via an A$20.7 million institutional placement and an A$0.96 million share purchase plan, and completed the divestiture of its Battery Technology Solutions unit to focus on North American synthetic graphite. NOVONIX’s growth plan is underpinned by substantial U.S. government support, including a $100 million DOE grant, $103 million in Section 48C tax credits, and a conditional DOE loan commitment of up to $754.8 million, though these remain contingent on meeting program conditions and project milestones.
Novonix Limited reports the issue of 171,591 new ordinary fully paid shares (ASX code NVX) following the exercise or conversion of performance rights under an employee incentive scheme. These new shares are additional securities in an existing quoted class and are intended to be quoted on ASX.
The shares are being issued for non-cash consideration, with the value per security estimated at AUD 0.150000. After quotation, total quoted ordinary shares will be 997,784,585, alongside several unquoted classes including performance rights, options, share rights, convertible notes and convertible debentures.
NOVONIX Limited is changing the ratio of its American Depositary Shares so that the current ratio of 1 ADS representing 4 ordinary shares will become 1 ADS representing 40 ordinary shares. This has the same effect as a one-for-ten reverse split of existing ADSs, with each 10 existing ADSs exchanged for 1 new ADS. The new ADS ratio is expected to become effective on 27 August 2026, and the ADSs will continue trading on Nasdaq under the ticker NVX. The change does not alter the number of NOVONIX ordinary shares on issue or affect the ordinary shares listed on the ASX. NOVONIX previously received notice that its ADSs were below Nasdaq’s US$1.00 minimum bid price for 30 consecutive business days and was given 180 calendar days to regain compliance. The ADS ratio change is intended to increase the per-ADS trading price and assist in regaining compliance, though there is no assurance this will occur.
NOVONIX Limited reported quarterly operational and cash flow details while progressing its strategic graphite anode active material business. The company delivered a mass-production C-sample of synthetic graphite AAM to Panasonic Energy, with internal testing indicating it meets specifications, and reaffirmed its target to begin mass production for Panasonic in the second half of 2027, subject to completion of qualification. It completed an institutional placement of A$20.7 million and raised A$0.96 million via a share purchase plan, and the U.S. Government certified the Riverside project in connection with a previously allocated US$103 million Section 48C tax credit. NOVONIX also closed the divestiture of its Battery Technology Solutions division.
For the quarter ended 30 June 2026, net cash used in operating activities was 8,642 $USD’000 and investing outflows were 2,441 $USD’000, while financing activities provided 13,226 $USD’000. Cash and cash equivalents were US$59.5 million, with estimated funding capacity of 6.9 quarters. Capital expenditures totaled 2,260 $USD’000, mainly for the Riverside facility, and related-party payments were US$281,000. The company has fully drawn US$40,000,000 in unsecured convertible debentures and a USD$30,100,000 real estate facility.
NOVONIX Ltd director Sharan Burrow reported acquiring 31,250 ordinary shares on 2026-07-22 in an "other" acquisition (transaction code J) at $0.16 per share. Following this transaction, Burrow directly holds 246,989 ordinary shares. The Rule 10b5-1 trading-plan checkbox is not marked.
Novonix Limited, a foreign private issuer, reported an update to director Sharan Burrow’s holdings. An issue of shares under the company’s Share Purchase Plan changed her direct relevant interest, and she now holds 246,989 ordinary shares and 195,938 share rights. No changes were reported to any related contracts, and it was confirmed that the interests were not traded during a closed period requiring prior written clearance.
NOVONIX Limited completed a Share Purchase Plan, issuing 6,016,250 fully paid ordinary shares at A$0.16 each to raise A$962,600 before costs. The offer, which closed on 17 July 2026, allowed eligible shareholders to apply for up to A$30,000 of new shares.
The company plans to use the proceeds to fund capital expenditure to support production capacity and forecast customer demand. Valid applications were received from approximately 89 eligible shareholders, with an average application of approximately A$10,816 and a participation rate of approximately 0.3% of eligible shareholders.
The 6,016,250 new SPP Shares represent approximately 0.6% of NOVONIX’s ordinary shares on issue. Following quotation, total ordinary fully paid shares quoted on ASX are 997,612,994.
NOVONIX Limited updated the timetable for its previously announced Share Purchase Plan (SPP). The SPP will now close at 5:00pm AEST on 17 July 2026, brought forward from the earlier closing date. Applications and payments must be received in cleared funds by that time, otherwise they will be rejected and application monies returned in full without interest.
The company targets announcing SPP results on or about 20 July 2026, with allotment of SPP shares on or about 22 July 2026 and trading expected to commence on or about 23 July 2026, subject to ASX confirmation and applicable rules.